Terguride--a new dopamine agonist drug: a comparison of its neuroendocrine and side effect profile with bromocriptine. by Ciccarelli, E, Touzel, R, Besser, M, Grossman, A

The growth hormone secretagogue receptor. by Korbonits, M, Ciccarelli, E, Ghigo, E, Grossman, AB

Long-term treatment with a new repeatable injectable form of bromocriptine, Parlodel LAR, in patients with tumorous hyperprolactinemia. by Ciccarelli, E, Miola, C, Avataneo, T, Camanni, F, Besser, G, Grossman, A

Subcutaneous growth hormone-releasing hormone augments pulsatile nocturnal GH release in GH-insufficient children, but may also raise basal GH secretion. by Ross, R, Kirk, J, Tsagarakis, S, Trainer, P, Ciccarelli, E, Touzel, R, Grossman, A, Savage, M, Besser, G

Somatostatin analogues stimulate p27 expression and inhibit the MAP kinase pathway in pituitary tumours. by Hubina, E, Nanzer, A, Hanson, MR, Ciccarelli, E, Losa, M, Gaia, D, Papotti, M, Terreni, MR, Khalaf, S, Jordan, S, Czirják, S, Hanzély, Z, Nagy, G, Góth, M, Grossman, AB, Korbonits, M

The efficacy and tolerability of long-term cabergoline therapy in hyperprolactinaemic disorders an open, uncontrolled, multicentre study by Ismail, I.S., Webster, J., Piscitelli, G., Polli, A., D'Alberton, A., Falsetti, L., Ferrari, C., Fioretti, P., Giordano, G., L'Hermite, M., Ciccarelli, E., Crosignani, P.G., DeCecco, L., Fadini, R., Faglia, G., Flamigni, C., Tamburrano, G., Scanlon, M.F.

Get full text